IO Biotech Statistics
Total Valuation
IO Biotech has a market cap or net worth of $77.74 million. The enterprise value is -$19.54 million.
Important Dates
The next estimated earnings date is Friday, November 15, 2024, before market open.
| Earnings Date | Nov 15, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
IO Biotech has 65.88 million shares outstanding. The number of shares has increased by 115.42% in one year.
| Shares Outstanding | 65.88M |
| Shares Change (YoY) | +115.42% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.23% |
| Owned by Institutions (%) | 20.86% |
| Float | 27.84M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.82 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.84, with a Debt / Equity ratio of 0.02.
| Current Ratio | 7.84 |
| Quick Ratio | 7.42 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -87.66% and return on invested capital (ROIC) is -56.75%.
| Return on Equity (ROE) | -87.66% |
| Return on Assets (ROA) | -50.98% |
| Return on Capital (ROIC) | -56.75% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.29M |
| Employee Count | 68 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, IO Biotech has paid $703,000 in taxes.
| Income Tax | 703,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +32.58% in the last 52 weeks. The beta is 0.42, so IO Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.42 |
| 52-Week Price Change | +32.58% |
| 50-Day Moving Average | 1.14 |
| 200-Day Moving Average | 1.40 |
| Relative Strength Index (RSI) | 49.13 |
| Average Volume (20 Days) | 91,316 |
Short Selling Information
The latest short interest is 277,050, so 0.42% of the outstanding shares have been sold short.
| Short Interest | 277,050 |
| Short Previous Month | 317,530 |
| Short % of Shares Out | 0.42% |
| Short % of Float | 1.00% |
| Short Ratio (days to cover) | 0.38 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -93.40M |
| Pretax Income | -87.64M |
| Net Income | -88.00M |
| EBITDA | -93.16M |
| EBIT | -93.40M |
| Earnings Per Share (EPS) | -$1.42 |
Full Income StatementBalance Sheet
The company has $100.75 million in cash and $2.15 million in debt, giving a net cash position of $98.60 million or $1.50 per share.
| Cash & Cash Equivalents | 100.75M |
| Total Debt | 2.15M |
| Net Cash | 98.60M |
| Net Cash Per Share | $1.50 |
| Equity (Book Value) | 96.27M |
| Book Value Per Share | 1.46 |
| Working Capital | 93.93M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$80.70 million and capital expenditures -$159,000, giving a free cash flow of -$80.86 million.
| Operating Cash Flow | -80.70M |
| Capital Expenditures | -159,000 |
| Free Cash Flow | -80.86M |
| FCF Per Share | -$1.23 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |